Novye preparaty dlya lecheniya virusnogo gepatita S: fokus na sofosbuvir


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

About the authors

E. A Ushkalova

Email: eushk@yandex.ru

References

  1. World Health Organization. Global Alert and Response: Hepatitis C. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index1.html
  2. Vezali E., Aghemo A., Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther. 2010; 32: 2117-38.
  3. Sangiovanni A., Prati G.M., Fasani P., Ronchi G., et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006; 43: 1303-310.
  4. Rosen H.R. Chronic Hepatitis C infection. N Engl J Med. 2011; 364: 2429-38.
  5. Di Bisceglie A.M. Hepatitis C and hepatocellular carcinoma. Hepatol. 1997; 26: 34S-38S.
  6. Gravitz L. Introduction: a smouldering public-health crisis. Nature. 2011; 474(7350): S2-S4.
  7. Rein D.B., Wittenborn J.S., Weinbaum C.M., Sabin M., Smith B.D., Lesesne S.B. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011; 43: 66-72.
  8. Ly K.N., et al. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007. Ann Intern Med. 2012; 156: 271-78.
  9. Volk M.I., Tocco R., Saini S., Lok, ASF. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009; 50(6): 1750-55.
  10. Dufour M.C. Chronic liver disease and cirrhosis. In Everhart J.E., ed. Digestive diseases in the United States: epidemiology and impact. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 1994; NIH publication no. 94-1447, 615-45.
  11. Pyenson B., Fitch K., Iwasaki K. Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease. Milliman, Inc. May 2009.
  12. Zeng Q.L., Zhang J.Y., Zhang Z., et al. Sofosbuvir and ABT-450: terminator of hepatitis C virus? World J Gastroenterol. 2013 Jun 7; 19(21): 3199-206.
  13. Wang L.F., Wang F.S., Manns M.P., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001; 358: 958-65.
  14. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonzales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-82.
  15. Hadziyannis S.J., Sette H., Morgan T.R., et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140: 346-55.
  16. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361: 580-93.
  17. Jacobson I.M., McHutchison J.G., Dusheiko G., et al.; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-16.
  18. Bacon B.R., Gordon S.C., Lawitz E., et al.; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl. J. Med. 2011; 364: 1207-17.
  19. Maasoumy B., Port K., Markova A.A., et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One. 2013; 8: e55285.
  20. Hezode C., Fontaine H., Dorival C., et al; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS C020-CUPIC) NCT01514890. J. Hepatol. 2013; 59: 434-41.
  21. Sulkowski M.S., Cooper C., Hunyady B., et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 2011; 8: 212-23.
  22. Heim M.H. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol. 2013; 13: 535-42.
  23. Park C., Jiang S., Lawson K.A. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther. 2013 Nov 16. [Epub ahead of print]
  24. Perry C.M. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs. 2012 Mar 26; 72(5): 619-41.
  25. Rowen K. Zetterman. HCV Treatment: Where We're At, Where We're Going. Medscape. Dec 11, 2013.
  26. Salam K.A., Akimitsu N. Hepatitis C virus NS3 inhibitors: current and future perspectives. Biomed Res Int. 2013; 2013: 467869. Epub 2013 Oct 27.
  27. Dusheiko G., Wedemeyer H. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.Gut. 2012; 61(12): 1647-52.
  28. Maasoumy B., Port K., Calle Serrano B. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther. 2013; 38( 11-12): 1365- 72.
  29. Seden K., Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS. 2011; 6(6): 514-26.
  30. Wilby K.J., Partovi N., Ford J.A., et al. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can. J. Gastroenterol. 2012; 26(4): 205-10.
  31. Carmona I.M., Rivas Y.D., Gonzalez-Perez C., et al. CPC-133 Telaprevir: Adverse Events in Clinical Practise. Eur. J. Hosp. Pharm. 2013; 20: A213.
  32. Telaprevir-related morbidity more common in real-world practice than trial settings http://www.healio.com/infectious-disease/hepatitis-resource-center-2013/anurag-maheshwari-md-on-telaprevir-based-hcv-treatment
  33. Hezode C., et al. Safety of telaprevir and boceprevir in combination with preginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO2 0-CUPIC). International Liver Congress. 2012. http://mobile.ilcapp.eu/EASL_161/poster_23756/program.aspx
  34. Akiyama M.J., Piotrowski J.I., Roytman M.M., et al. New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. Hawaii J. Med. Public. Health. 2013; 72(9 Suppl 4): 6-13.
  35. Important safety information and labeling changes for Incivek (telaprevir) http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm333260.htm
  36. Victrelis (boceprevir) labeling update http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm32 6690.htm
  37. Lok A.S., Gardiner D.F., Lawitz E., Martorell C., Everson G.T., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012; 366: 216-24.
  38. Backus L.I., Belperio P.S., Shahoumaian T.A., Cheung R., Mole L.A. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large US cohort. Aliment Pharmacol. Ther. 2014; 39: 93-103.
  39. Bichoupan K., Martel-Laferriere V., Ng M., et al. Real world costs of telaprevir-based triple therapy, including costs of managing adverse events, at the Mount Sinai Medical Center, NY: $195,000 per SVR12. Hepatology. 2013; 58(Suppl): 329A-330A.
  40. You D.M., Pockros P.J. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2013; 14(18): 2581-89.
  41. Fried M., Buti M., Dore G.J., et al. TMC435 in combination with peginterferon and ribavirin in treatment naive HCV genotype 1 patients: final analysis of the PILLAR phase II b study. Proceedings of the 62nd Annual Meetgin of the American Assoication for the Study of Liver Diseases.San Francisco, Calif, USA. 2011.
  42. Chae H.B., Park S.M., Youn S.J. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives. Scientific World J. 2013; 2013: 704-912.
  43. Forns X., Lawitz E., Zeuzem S., et al. Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013). Washington, DC, 2013. Abstract1092.
  44. Jacobson I.M. SVR results of a once-daily regimen of simeprevir (TMC-438) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Program and abstracts of American Association for the Study of Liver Diseases The Liver Meeting®. 2013. Abstract LB-3.
  45. Симепревир - совершенно новый препарат против гепатита С. http://hepatitis-c.org.ru/%0D1%81%D0%B8%D0%BC%D0%B5%D0%BF%D1%80%D0%B5%D0%B2%D0%B8%D1%80
  46. Joost P.H. Drenth, HCV Treatment - No More Room for Interferonologists? N. Engl. J. Med. 2013; 368: 1931-32.
  47. Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother. 2014; 15(1): 121-30.
  48. Jacobson I.M., Gordon S.C., Kowdley K.V., et al; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 2013; 368: 1867-77.
  49. Lawitz E., Mangia A., Wyles D., et al.Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16; 368(20): 1878-87.
  50. Kowdley K. Hepatitis C Drug Sofosbuvir Still Effective at 24 Weeks. American College of Gastroenterology (ACG) 2013 Annual Scientific Meeting and Postgraduate Course: Abstract 38. Presented October 15, 2013.
  51. U.S. Food and Drug Administration Approves Gilead's Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C December 6, 2013. http://www.drugs.com/newdrugs/fda-approves-sovaldi-chronic-hepatitis-c-3986.html
  52. Younossi Z.M., Stepanova M., Henry L., et al. Minimal Impact of Sofosbuvir and Ribavirin on Health Related Quality of Life in Chronic Hepatitis C ( CH-C). J Hepatol. 2013 Dec 10. [Epub ahead of print]
  53. Gane E.J., Stedman C.A., Hyland R.H., et al. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin: the ELECTRON study. Hepatology. 2013; 58(Suppl): 243A-4A.
  54. Food and Drug Administration Approves Gilead's Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C. http://finance.yahoo.com/news/u-food-drug-administration-approves-211900093.html
  55. Сострадательный доступ к софосбувиру: 666 евро за таблетку. http://www.itpcru.org/news/post_491.html
  56. Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients. Nov 2, 2013 http://hepatitiscnewdrugs.blogspot.ru/2013/11/aasld-gilead-announces-new-sustained.html
  57. Hepatite C: l'Agence europeenne du Medicament recommande l'AMM de sofosbuvir (Sovaldi) Nov 22, 2013 http://www.seronet.info/article/hepatite-c-lagence-europeenne-du-medicament-recommande-lamm-de-sofosbuvir-sovaldi-64554
  58. How Much? A Battle Over The Cost Of The New Hepatitis C Drugs http://www.pharmalive.com/how-much-a-battle-over-the-cost-of-the-new-hepatitis-c-drugs

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies